tfg/data/attachment/portal/202109/01 |
您所在的位置：网站首页 › tfg/data/attachment/portal/202109/01 |
data-id="" >Daiichi Sankyohttps://www.daiichisankyo.com/files/news/pressrelease/pdf/202109/20210917_E1.pdf[PDF]FINAL - DS-7300 ESMO Data Press Release 09162021网页2021年9月17日 · DS-7300 is an investigational B7-H3 directed ADC and is one of six ADCs currently in clinical development in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-7300 is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an ...
发布时间：2024-04-29